Schizophrenia
Upcoming SlideShare
Loading in...5
×
 

Schizophrenia

on

  • 1,651 views

presentazione tratta dal sito del Centre for clinical Brain Science (http://www.ccbs.ed.ac.uk/default.asp) sulla genetica della schizofrenia

presentazione tratta dal sito del Centre for clinical Brain Science (http://www.ccbs.ed.ac.uk/default.asp) sulla genetica della schizofrenia

Statistics

Views

Total Views
1,651
Views on SlideShare
1,575
Embed Views
76

Actions

Likes
0
Downloads
37
Comments
0

3 Embeds 76

http://www.polygenicpathways.co.uk 73
http://www.slideshare.net 2
http://polygenicpathways.co.uk 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Schizophrenia Schizophrenia Presentation Transcript

  • Discovering Disease Genes- The Example of Schizophrenia Pippa Thomson, Medical Genetics Section, Dept of Medical Sciences, MMC, University of Edinburgh.
  • Importance of the illness
    • Severe psychiatric
    • Affects ~1% of the population
    • One of the top 10 causes of disability worldwide
    • Economic cost (23% Drug, 14% Hospital)
    • Pharmacological rationale for treatment weak or absent
    • 1/3rd patients unresponsive or experience unacceptable side effects
    • Strong genetic component
      • concordance rate between identical twins of 60%
  • Schizophrenia Positive symptoms: visual & auditory hallucinations, delusions, incoherent speech
  • Schizophrenia Negative symptoms: withdrawal & isolation, impaired attention & blunted emotions
  • Altered brain structure & function
  • High Heels Cause Schizophrenia and 6 Other Outlandish Medical Theories 2. High-heeled shoes cause schizophrenia. You have to wonder where some medical theories originate. Why did Swedish scientist Jarl Flensmark decide to study a connection between heeled shoes and the incidence of schizophrenia ? The world may never know. But his initial research seems sound, and he has connected certain brain activity with stimulation of certain points on the feet. The spread of schizophrenia around the globe has closely followed the spread of availability of heeled shoes. Is it an eerie coincidence or a real cause for concern? Look out, men - this theory applies not only to stilettos, but to any shoe with a heel. remedicated.com
  • Relative risk of developing Schizophrenia Environment !
  • Benefits of gene identification
    • Understand aetiology
    • Improved drug development & testing
    • Development of definitive diagnostic tests
    • Understanding of interaction with non-genetic risk factors
    • Insight into normal brain development & function
    Kraepelin, 1896 “ As we do not know what causes the illness there cannot be a rational treatment”
  • Allelic architecture and mapping strategy Magnitude of effect Frequency in population Family-based linkage studies Association studies in populations Unlikely to exist Fnct. Studies
  • Locus Identification-problems
    • Uncertainty in diagnostic boundaries
    • Non-Mendelian inheritance
    • Variable age of onset
    • Genetic heterogeneity
      • Many different genes can cause the illness
        • 1% risk world wide
        • phenotypic variation
    • Oligogenic/polygenic causation
      • More than one mutant gene required to produce phenotype
  • Locus identification- reducing the problems
    • Single large families
    • Avoid bilineal descent
        • rigorous interviews
        • family history
    • Reduce genetic heterogeneity
    • Significant LOD score = gene of major effect
    • Reduce uncertainty of diagnosis
      • classify minor diagnoses as unaffected
      • >1 category of affected phenotype
    • Marker analysis in multiply affected family or families
    • Look for co-segregation of a particular allele with phenotype
    • Results expressed as a LOD score (Significant at > 3)
    • = log (likelihood of data, if locus & disease are linked)
    • ----------------------------------------------------------------
    • (likelihood of data, if locus & disease are not linked)
    • Generally a large region is identified
    Linkage Analysis
  • A balanced t(1;11)(q42;q14) translocation der1 der11 11 1 1 1q42 11q14 11
  • ? recurrent major depression minor diagnosis unaffected schizophrenia bipolar affective disorder (1;11)(q42;q14) translocation translocation increases risk by 50-fold t(1;11) co-segregates with major mental illness
    • Genetic association studies seek to relate variation in human DNA sequence with a disease or trait
    • Association method provides greater power to detect common genetic variants conferring susceptibility to complex phenotypes
    • Estimates population attributable risk (effect size)
    • Controls should match cases and be a representative sample of the population.
    Controls Schizophrenics 100’s Individuals = 1% Schizophrenia 100’s Individuals = 100% Schizophrenia
  • Case-control association studies
    • Comparison of frequencies of polymorphisms between populations of cases and controls (usually a simple chi-square test or logistic regression)
    • Polymorphism studied can be directly responsible for the defect  frequency of cases >>> controls
    • Polymorphism studied can be in linkage disequilibrium with the mutation responsible for the disease  %T cases >> controls
    • Association studies can be conducted for candidate genes, or through a whole region or across the whole genome (WTCCC)
    p Mb T A G C
  • SNPs are genotyped in parent-offspring trios, initially in CEPH trios. This can be used to identify SNPs that co-segregate (i.e. are in linkage disequilibrium) versus those that segregate independently. A subset of SNPs can therefore be chosen that best represent the genetic diversity in a region/gene, reducing the costs of genotyping. Summary of genotyped SNPs: Populations CEU CHB+JPT YRI Total Non-Redundant 3,204,709 3,244,897 3,150,433 International HapMap project http://www.hapmap.org/
  • Region of interest HapMap genotyped SNPs Known SNPs* Known genes in the regions Linkage Disequilibrium (LD) *http://www.ncbi.nlm.nih.gov/SNP/
  • Tagging SNP selection Proportion of haplotype diversity explained : SNPs 1-23 - 97% SNPs 24-46 - 98%
  • DISC2 TRANSLOCATION LOD=7.1, SCOTLAND Genetic evidence implicating DISC1 in psychiatric illness 1 SCZ & BPAD & MDD SCOTLAND SCZ , BPAD HAPLOTYPE p =0.0044, p =0.0016 2 3 4 5 6 7 8 9 10 11 12 13 DISC1 LOD=2, BRITAIN & ICELAND (Curtis et al 2003) D1S251 LOD=1, TAIWAN (Hwu et al 2003) SCZ BPAD HAPLOTYPE p =0.00024, FINLAND (Hennah et al 2003) SCZ & SCZAFF LOD=3.21, FINLAND (Ekelund et al 2001) SCZ D1S2709 p =0.000027, North-America (Hodgkinson et al 2004) rs6675281 SCZAFF
  • Table 1. Summary of current evidence supporting several of the more promising genes implicated in schizophrenia, bipolar disorder, and mixed bipolar-psychosis phenotypes Craddock et al., SCZ Bulletin, 2006 Genes for Schizophrenia ? >130 genes implicated
  • DISC1 interactome protein-protein interactions Chris Carter, http://www.polygenicpathways.co.uk/disc11_vml.htm
    • ENU generated mouse mutants
    • Two independent lines with missense mutations in DISC1 exon 2
      • Q31L (Glutamine-Leucine)
        • Q- hydrophillic; L – hydrophobic
      • L100P (Leucine-Proline)
        • Predicted to cause transition in polypeptide chain direction
    • Normal levels of DISC1 protein in brain
    • L100P line models schizophrenia; Q31L, depression
    Effects of altered DISC1 on gene expression Clapcote et al., Neuron. 2007 May 3; 54 ( 3 ): 387-402 .
  • Schizophrenia Depression Effects of Altered DISC1 on Behaviour ( How do you know if a mouse is schizophrenic? )
  • Effects of altered DISC1 on gene expression
    • Samples collected and microarray study ongoing
      • Mutated lines vs background strain (C57/BL6)
      • 47,000 transcripts
      • Hippocampus
      • Adult and embryonic stage- Microarray
      • Confirmation/Investigation of changes
        • Series of embryonic; postnatal and adult stages
        • Drug treated adult mice
    Detect disrupted pathways
    • Resequencing, SNP detection, genome comparisons, gene expression, transcription factor studies, small RNA analysis
    • Individual genomes – All SNPs in each individual
    • Currently :
    • Using the Illumina 1G to sequence genes in the DISC1 pathway.
    • Total sequence read 3.5megabases in 1200 individuals
    • Identify coding and non-coding polymorphisms
    • Mutation detection
    • Detection of variants in conserved regions
    • Detection of variants affecting binding of transcription factors
    Whole genome sequencing
  • Psychiatric Genetics- Unanswered Questions
    • How many susceptibility genes are there? What is their function? Is function conserved across species? Can we relate gene (dys)function to mental (dis)order? Do gene variants predict risk, course, outcome and response to treatment? Will gene discovery lead to drug discovery? How do genes and environment interact? How and when will the patient benefit?
  • DISC1 Kirsty Millar Shaun Mackie Fumiaki Ogawa Jennifer Chubb Becky Carlyle Nick Bradshaw Sheila Christie Steve Clapcote Kathy Evans Sarah Brown William Hennah Medical Genetics Prof David Porteous Prof Douglas Blackwood Walter Muir Ben Pickard Other collaborators DISC1 Consortium Wellcome Trust CRF Illumina, San Diego Cold Spring Harbor laboratories Acknowledgements